AzTrials
AzTrials

Behcet DiseasePhase 3SHIELDNCT00995709

Phase III Study in Refractory Behcet's Disease

A Phase 3 study testing AIN457 in people with Behcet Disease, run by Novartis Pharmaceuticals at 49 sites in 17 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Behcet Disease
What is being tested?
AIN457
Type of treatment
Injection or infusion
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
118 participants
Where
49 sitesin 17 countries
Study dates
Oct 2009to Jul 2010
Phase
Phase 3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patients with Behçet's disease and with a history of recurrent uveitis in a least one eye.
  • Documented evidence of >2 recurrent exacerbations of either intermediate uveitis, posterior uveitis or panuveitis in the study eye within the past 6 months (this could include the current exacerbation for patients having an acute exacerbation at screening). Exacerbations fulfilling the study inclusion criteria must have one or more of the following recorded in the patients patients medical record for each recurrent exacerbation:
  • >2+ vitreous haze with <2+ anterior chamber cell grade (intermediate or posterior uveitis) or >2+ vitreous haze with >2+ anterior chamber cell grade (panuveitis)
  • presence of retinal infiltrates or vasculitis or hemorrhages
  • documented >10 ETDRS letter or 2 line Snellen decrease in visual acuity attributed to ocular inflammation secondary to the recurrent exacerbation of Behçet's disease.
  • Requirement for either of the following immunosuppressive therapies for at least 3 of the past 6 months for the treatment of or to prevent an exacerbation of ocular inflammation related to Behçet's disease:
Show all 10Show fewer
  • Prednisone or equivalent >10 mg daily
  • The need for at least >1 periocular injection or >1 intravitreal corticosteroid injection in the study eye within the past 6 months (the last injection must have not been given within 6 weeks of screening)
  • Treatment with cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolic acid or methotrexate either as monotherapy or in combination with or without steroids. (Patients treated at any time with chlorambucil or cyclophosphamide are not eligible for the study.)
  • Patients not meeting the above specified criteria for immunomodulatory therapies are eligible for enrollment if they are intolerant to systemic immunomodulatory therapy as determined by the study investigator.

Who cannot join

  • Subjects with infectious uveitis, uveitis due to other causes than Behçet's disease, or uveitis of unknown etiology.
  • Less severe (i.e. anterior) uveitis associated with Behçet's disease.
  • Ocular treatments
  • Treatment with intravitreal anti-VEGF agents administered to the study eye within 3 months prior to study screening.
  • Treatment with any injected or implantable corticosteroid releasing device (i.e., flucinolone acetonide implant, Retisert®) in the study eye within the last 3 years.
  • Intraocular surgery or laser photocoagulation in the study eye within the last 6 weeks prior to screening except for a diagnostic vitreous or aqueous tap with a small-gauge needle.
Show all 11Show fewer
  • Systemic conditions or treatments
  • Treatment with any live or live-attenuated vaccine (including vaccine for varicella-zoster virus or measles) within 2 months prior to screening.
  • Any systemic biologic therapy (e.g. interferon, infliximab, daclizumab, etanercept, or adalimumab) given intravenously or subcutaneously within 3 months prior to screening and no prior treatment with AIN457.
  • Any prior treatment with systemic alkylating agents (cyclophosphamide, chlorambucil).
  • Other protocol-defined inclusion/exclusion criteria may apply

Trial locations and contacts

49 sites in 17 countries.

49 sites in 17 countries

Greece8 sites
  • Novartis Investigative Site

    Athens, Greece, GR 156 69

  • Novartis Investigative Site

    Athens, GR, 115 27

  • Novartis Investigative Site

    Heraklion - Crete, GR, 711 10

  • Novartis Investigative Site

    Ioannina, GR, 455 00

  • Novartis Investigative Site

    Ioannina, 45500

  • Novartis Investigative Site

    Larissa, Greece, GR 41110

  • Novartis Investigative Site

    Larissa, GR, 41110

  • Novartis Investigative Site

    Pátrai, 26500

Other trials in Greece

Turkey (Türkiye)6 sites
  • Novartis Investigative Site

    Altindag / Ankara, 06590

  • Novartis Investigative Site

    Ankara, Turkey, 06100

  • Novartis Investigative Site

    Ankara, Turkey, 06490

  • Novartis Investigative Site

    Istanbul, 34093

  • Novartis Investigative Site

    Istanbul, 34303

  • Novartis Investigative Site

    Izmir, 35380

Other trials in Turkey (Türkiye)

Germany4 sites
  • Novartis Investigative Site

    Dessau, 06847

  • Novartis Investigative Site

    Essen, 45147

  • Novartis Investigative Site

    Heidelberg, 69120

  • Novartis Investigative Site

    Münster, 48145

Other trials in Germany

India4 sites
  • Novartis Investigative Site

    Angamaly, 683572

  • Novartis Investigative Site

    Chennai, Tamil Nadu, 600006

  • Novartis Investigative Site

    Madurai, Tamil Nadu, 625020

  • Novartis Investigative Site

    New Delhi, 110 029

Other trials in India

Israel4 sites
  • Novartis Investigative Site

    Afula, 18101

  • Novartis Investigative Site

    Nahariya, 22100

  • Novartis Investigative Site

    Ramat Gan, 52621

  • Novartis Investigative Site

    Tel Aviv, 64239

Other trials in Israel

Spain4 sites
  • Novartis Investigative Site

    Barcelona, Barcelona, 08035

  • Novartis Investigative Site

    Barcelona, Catalonia, 08028

  • Novartis Investigative Site

    Barcelona, Catalonia, 08035

  • Novartis Investigative Site

    Barcelona

Other trials in Spain

United States3 sites
  • Novartis Investigative Site

    Arlington, Texas, 76012

  • Novartis Investigative Site

    Baltimore, Maryland, 21205-2005

  • Novartis Investigative Site

    Houston, Texas, 77025

Other trials in United States

Tunisia3 sites
  • Novartis Investigative Site

    Monastir, 5019

  • Novartis Investigative Site

    Sfax

  • Novartis Investigative Site

    Tunis

Other trials in Tunisia

Italy2 sites
  • Novartis Investigative Site

    Ancona, AN, 60126

  • Novartis Investigative Site

    Milan, MI, 20132

Other trials in Italy

Jordan2 sites
  • Novartis Investigative Site

    Amman, 11195

  • Novartis Investigative Site

    Irbid, 22110

Other trials in Jordan

South Korea2 sites
  • Novartis Investigative Site

    Seoul, Korea, 110 744

  • Novartis Investigative Site

    Seoul, Korea, 120-752

Other trials in South Korea

Switzerland2 sites
  • Novartis Investigative Site

    Bern, 3012

  • Novartis Investigative Site

    Lausanne, Switzerland, 1003

Other trials in Switzerland

Egypt1 site
  • Novartis Investigative Site

    Alexandria

Other trials in Egypt

France1 site
  • Novartis Investigative Site

    Grenoble, 38043

Other trials in France

Hong Kong1 site
  • Novartis Investigative Site

    Hong Kong, Hong Kong

Other trials in Hong Kong

Singapore1 site
  • Novartis Investigative Site

    Singapore, Singapore, 308433

Other trials in Singapore

Taiwan1 site
  • Novartis Investigative Site

    Lin-Ko, 33305

Other trials in Taiwan

About this study

Official title: A 24 Week Multicenter, Randomized, Double-masked, Placebo Controlled Study to Assess the Difference in the Rate of Recurrent Exacerbations in Behçet¿s Patients With Posterior or Panuveitis Treated With AIN457 vs Placebo Adjunctive to Standard-of-care Immunosuppressive Therapy

The purpose of this pivotal trial is to evaluate subcutaneous (SQ) AIN457 as an adjunctive therapy to reduce the rate of exacerbations of posterior uveitis or panuveitis secondary to Behçet's disease during the 24 weeks of study therapy as compared to standard of care alone.

Conditions
Behcet Disease
Being tested
AIN457, Placebo
Keywords
Behçet's disease,, intermediate uveitis, panuveitis, posterior uveitis, uveitis
Medical subject headings
Behcet Syndrome, Uveitis, Intermediate, Panuveitis, Uveitis, Posterior, Uveitis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AIN457Drug

  • AIN457Drug

  • PlaceboDrug

Study groups in NCT00995709
Study groupRoleWhat they receive
AIN457C 300 mg every 2 week dosage regimenExperimentalAIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg each. every 2 weeks
Receives: Drug: AIN457
AIN457C 300 mg monthly dosage regimenExperimentalAIN457 300 mg was administered in 2 subcutaneous (s.c.) injections of 150 mg e
Receives: Drug: AIN457
PlaceboPlacebo comparatorPlacebo was administered in 2 s.c. injections every 2 weeks
Receives: Drug: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment

    Measured: Baseline to week 24

  2. Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment

    Patients number of occurences during a 24 week period.

    Measured: 24 weeks

Secondary outcomes (4)
  1. Change From Baseline for Composite Immunosuppressive Medication Score at Week 24 by Treatment (Full Analysis Set)

    For each corticosteroid medication, dose of the corticosteroid was first converted to a prednisone-equivalent dose. To determine the prednisone equivalent dose, the corticosteroid dose was multiplied by a conversion factor. . The total prednisone equivalent dose was calculated as the sum of the prednisone equivalent doses of all corticosteroids. Consequently, the total converted prednisone equivalent dose was used to obtain the immunosuppressive score. The key secondary efficacy variable was the change in total post-baseline immunosuppressive medication score from baseline.The score is actually the prednisoone equivalents taken by patient as calculated by conversion table. A reduction in prenisone or prenisone equivalents is a positive outcome. An increase in the number of prednisone equivalents suggests that the treatment is not efficacious or that there is disease progression. A score of 0 would be the lowest ( no steriods taken) and the upper limit is indeterminate.

    Measured: 24 weeks

  2. To Determine the Effect of AIN457 on Macular Edema and Visual Acuity in Patients With Posterior Segment Uveitis Secondary to Behçet's Disease as Determined by Optical Coherence Tomography.

    Optical coherence tomography (OCT) is amedical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media (e.g., biological tissue). OCT is based on low-coherence interferometry, typically employing near-infrared light. The use of relatively long wavelength light allows it to penetrate into the scattering medium. OCT is a noninvasive procedure that uses optical interferometry to visualize the structures within the retina. Following dilation of the pupil, a light source operating at 850nm provides probe illumination which is split and detected with and without the refraction of the retinal tissues. Cross-sectional imaging is accomplished in 1.3 second by acquiring a sequence of interferometric A-scans. A false color tomogram of optical reflectivity is produced by the computer. Central foveal thickness will be the primary variable derived from OCT. A increase in thickness could translate to disease progression.

    Measured: baseline, and wk 24 (end of study)

  3. To Establish the Impact of AIN457 on Quality of Life of Posterior Segment Uveitis Patients Secondary to Behçet's Disease Refractory to Systemic Immunomodulatory Therapy as Measured by National Eye Institute Visual Function Questionaire-25 and Euroqol.

    The VFQ-25 is a reliable and valid 25-item version of the 51-item National Eye Institute Visual Function Questionnaire (NEI-VFQ). It is especially useful in settings such as clinical trials, where interview length is a critical consideration. Scores range from 0 to 100, with higher scores indicating better visual function.

    Measured: screening, and wk 24 (end of study)

  4. To Observe the Effect of AIN457 on the Systemic Non-ocular Manifestations of Behçet's Disease in Patients With Posterior Segment Uveitis Requiring Systemic Immunosuppression as Measured by the Bechet's Disease Current Activity Form.

    The BDCAF scores oral and genital ulceration, skin, joint and gastrointestinal involvement, presence of fatigue and headache according to the duration of symptoms. The presence and type of large-vessel and central nervous system (CNS) involvement are documented. Eye activity was deemed present if there was a history of blurring of vision or if the eye was painful or red. . The BDCAF score was calculated by adding the score of each index and ranged between 0 and 12 A reduction in score signifies a lessening of the disease.

    Measured: baseline and wk 24 (end of study)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted15 Oct 2009 (estimated)
  2. Study startOct 2009
  3. Primary completionJul 2010
  4. Study completionJul 2010

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
118 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00995709
Sponsor's protocol ID
CAIN457C2303
Other IDs
2009-011237-27, 2009
Acronym
SHIELD
Status last verified
Aug 2015
First submitted
13 Oct 2009
Last updated
31 Aug 2015

Publications

  • Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, Androudi S. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology. 2013 Apr;120(4):777-87. doi: 10.1016/j.ophtha.2012.09.040. Epub 2013 Jan 3.

    PubMed 23290985

Questions about this trial

What is this clinical trial studying?

A Phase 3 study testing AIN457 in people with Behcet Disease, run by Novartis Pharmaceuticals at 49 sites in 17 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 10 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 31 Aug 2015. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 49 sites in Greece, Turkey (Türkiye), Germany, India, Israel and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 31 Aug 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment (time frame: Baseline to week 24). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00995709, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Aug 2015.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in